Bupivacain is one of 258 small molecule programs targeting Hip Fracture. It is currently in Phase 3.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
136 competitors in Atrial Fibrillation
Bupivacain
Calquence
Rituxan
Coumadin
Brukinsa
Versed
Ondexxya
Romazicon
Statin
Low-Molecular-Weight Heparin
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Sources
Details